APA (7th ed.) Citation

M, M., F, R., A, N., A, P., V, P., E, V., . . . E, A. (2025). Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies. Biomedicines, 13(12), . https://doi.org/10.3390/biomedicines13123044

Chicago Style (17th ed.) Citation

M, Marino, Rosset F, Nervo A, Piovesan A, Pala V, Vaccaro E, Mastorino L, Calogero AE, and Arvat E. "Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies." Biomedicines 13, no. 12 (2025). https://doi.org/10.3390/biomedicines13123044.

MLA (9th ed.) Citation

M, Marino, et al. "Cutaneous Adverse Events of Tyrosine Kinase Inhibitors in Endocrine Tumors: Clinical Features, Mechanisms, and Management Strategies." Biomedicines, vol. 13, no. 12, 2025, https://doi.org/10.3390/biomedicines13123044.